Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Burghaus2011 - Simulating Rivaroxaban effects on blood coagulation

ABSTRACT: Another mathematical model of blood coagulation.

SUBMITTER: Matthew Roberts

PROVIDER: MODEL1805140001 | BioModels | 2018-05-21

REPOSITORIES: BioModels

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MODEL1805140001?filename=Burghaus2011.cps	Other
	MODEL1805140001?filename=Burghaus2011.xml	Xml
	MODEL1805140001?filename=figure4.png	Other

Items per page:

1 - 3 of 3

Publications

Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.

Burghaus Rolf R Coboeken Katrin K Gaub Thomas T Kuepfer Lars L Sensse Anke A Siegmund Hans-Ulrich HU Weiss Wolfgang W Mueck Wolfgang W Lippert Joerg J

PloS one 20110422 4

Rivaroxaban is an oral, direct Factor Xa inhibitor approved in the European Union and several other countries for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery and is in advanced clinical development for the treatment of thromboembolic disorders. Its mechanism of action is antithrombin independent and differs from that of other anticoagulants, such as warfarin (a vitamin K antagonist), enoxaparin (an indirect thrombin/Factor Xa inh ...[more]

PMID: 21526168

Similar Datasets

Nagashima2002 - Simulating blood coagulation inhibitory effects

Project description:Mathematical model of blood coagulation and the effects of inhibitors of Xa, Va:Xa and IIa.

2024-09-02 | BIOMD0000000747 | BioModels

Burghaus2014 - Simulating blood coagulation factor Xa inhibitors

Project description:Mathematical model of blood coagulation factors II, VII, IX and X as well as protein C and protein S and the effect of warfarin on kinetic rates.

2018-07-18 | MODEL1807180005 | BioModels

Bio-inorganic interactions on zeolite surface in blood coagulation

Project description:Bio-inorganic interactions on zeolite surface in blood coagulation

2021-02-11 | PXD024170 |

Self-anticoagulant sponges for whole blood auto-transfusion and its mechanism of coagulation factor inactivation

Project description:Clinical use of intraoperative auto-transfusion requires the removal of platelets and plasma proteins due to the pump-based suction and water-soluble anticoagulant administration, which causes dilutional coagulopathy. Herein, we develop a carboxylated and sulfonated heparin-mimetic polymer-modified sponge that could spontaneously adsorb blood (1.149 kg/m-2 s-1/2) along with instantaneous anticoagulation. We demonstrate that intrinsic coagulation factors (especially XI) are inactivated by adsorption to the sponge surface, while inactivation of thrombin in the sponge-treated plasma effectively inhibits the common coagulation pathway. Benefiting from the multiple inhibitory effects of sponge on coagulation enzymes and calcium depletion, the whole blood auto-transfusion in trauma-induced hemorrhage is unprecedentedly realized. The transfusion of collected blood favors faster recovery of hemostasis compared to traditional heparinized blood in an animal model. Our work not only develops a safe and convenient approach for whole blood auto-transfusion, but also provides the mechanism of action of self-anticoagulant heparin-mimetic polymer-modified surfaces.

2023-07-23 | PXD044005 | Pride

Hartmann2016 - Blood coagulation model for simulating anticoagulants

Project description:Mathematical model of blood coagulation. Reused Wajima2009 model with modifications to reactions 27 (formation of Va:Xa complex), 32 (Xa inhibition by TFPI) and 45 (Xa inhibition by TFPI-Heparin complex) as described in publication equations 2,3 and 4. Publication lists parameter sets to simulate Rivaroxaban, VKA and Enoxaparin (supplementary files).

2018-07-18 | MODEL1807180004 | BioModels

Mitrophanov2015 - Simulating extended Hockin Blood Coagulation Model under varied pH

Project description:Mathematical model of the blood coagulation cascade with new kinetic rates to simulate acidosis. Extended Hockin2002 model. Reused Mitrophanov2011 model with new parameters k: 5, 6, 7, 10, 15, 16, 17, 22, 26, 31, 32, 43 and 44.

2024-09-02 | BIOMD0000000951 | BioModels

Pneumococcal BgaA promotes host organ bleeding and coagulation in mouse sepsis model

Project description:Streptococcus pneumoniae is a major cause of invasive diseases, such as pneumoniae, meningitis and sepsis resulting in high mortality. The molecular mechanisms and disease developing mechanism underlying pneumococcal infection remain unknown. Previously, we reported that S. pneumoniae β-galactosidase (BgaA) is evolutionarily conserved and contributes to pneumococcal pathogenesis in mouse sepsis model. BgaA is also known to play a role in pneumococcal growth, resistance to human neutrophil opsonophagocytic killing, bacterial adherence to human epithelial cells. In this study, since the detailed role that BgaA plays in sepsis remain unknown, we focused on the role of BgaA in pneumococcal sepsis. Our in vitro assays showed that BgaA promoted bacterial association with human lung epithelial and vascular endothelium cells. BgaA also contributes to pneumococcal survival with human blood by suppressing neutrophils killing, whereas BgaA did not affect pneumococcal survival in mouse blood. In a mouse sepsis model, mice infected with S. pneumoniae bgaA deletion mutant strain exhibited up-regulated host innate immunity pathways, and suppressed tissue damages and blood coagulation as compared to mice infected with the wild-type strain. These results suggest that BgaA works as a multifunctional virulence factor for inducing host tissue damages and blood coagulation. BgaA could be an attractive target for drug and vaccine development.

2022-07-18 | GSE190418 | GEO

Effect of MSC and MSC-derived extracellular vesicles on human blood coagulation

Project description:Mesenchymal stem cells (MSC) have emerged as potent therapeutic tool for a number of pathologies, including immune ones. However, unwelcome effects of MSC on the blood coagulation were revealed in some cases, which require more in-depth analysis. In this study, we explored the trombotic properties of human MSC from umbilical cord. We revealed strong procoagulant effects of umbilical cord MSC toward human and rat whole blood and platelets-free plasma using rotational thromboelastometry and thrombodynamics tests. The similar potentiation of clotting was demonstrated for MSC-derived extracellular vesicles (EV). In order to suggest approaches to avoid unwanted effects we studied the impact of heparin supplement on MSC/EV procoagulation properties. We found that therapeutic doses of unfractionated heparin injected in the patient's blood (administered in vivo) did not abrogate the procoagulant properties of MSC. Mass-spectrometry analysis of proteins of MSC and EV involved in coagulation-associated pathways was used to evaluate mechanisms of protrombotic effects.

2019-03-26 | PXD012768 | Pride

Rojano2019 - Blood Coagulation Model

Project description:Blood coagulation mathematical model derived from Chatterjee et al. (2010) and Hockin et al. (2002). Included various inhibitors: TFPI, ATIII, generic kallikrein inhibitor, C1-inhibitor, alpha1-antitrypsin and alpha2-antiplasmin.

2019-07-12 | MODEL1907120001 | BioModels